The estimation of eprosartan mesylate in pharmaceutical dosage forms by RP-HPLC

A simple, precise, rapid and accurate reverse phase HPLC method developed for the estimation of Eprosartan mesylate in tablet dosage form. An Xterra KP18 150x4.6 mm, 5 mu m partical size, with mobile phase consisting of acetonitrile and 0.03 M potassium dihydrogen phosphate (pH adjusted to 3.0 +/- 0.05 with orthophosphoric acid) in the ratio of 35:65 v/v was used. The flow rate was 1 ml/min and the effluents were monitored at 215 nm. The retention time was 5.549 min. The detector response was linear in the concentration of 1-25 mcg/ml. The respective linear regression equation being Y=6669.355x+892.3405. The limit of detection and limit of quantification was 0.1 and 0.5 mcg/ml respectively. The percentage assay of Eprosartan mesylate was 99.77 %. The method was validated by determining its accuracy, precision and system suitability. The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of Eprosartan mesylate in bulk drug and in its pharmaceutical dosage form.